Five things for pharma marketers to know: Thursday, August 18, 2016

1. A federal court ruled that Pfizer's biosimilar of Johnson & Johnson's blockbuster autoimmune drug Remicade does not infringe on the patent. The biosimilar, which was developed by Celltrion, is expected to come to market in October. (WSJ)

2. McDonald's pulled activity trackers it had been giving out in Happy Meals in the U.S. and Canada. Some users had reported skin irritation. (Ad Age)

3. A state lawmaker who introduced legislation in California to require drugmakers to explain drug-price hikes pulled the bill after amendments softened the intent of the legislation. (California Healthline)

4. Auris Medical said its experimental drug to treat acute inner ear tinnitus failed to meet two effectiveness goals in a Phase-III clinical trial. The trial compared the drug to a placebo. (Reuters)  

5. ICYMI: A large clinical trial of a new osteoporosis drug developed by Radius Health found that the drug can stimulate bone growth and prevent fractures as well as the current market leader. Here's what David Snow, Radius Health's chief commercial officer, has in store for the experimental therapy. (NYT)